Advancing Desmoid Tumor Science
The 2026 grant cycle is OPEN.
The DTRF funds research that will advance current scientific knowledge about desmoid tumors, moving toward the development of new treatment options and bringing us closer to our ultimate goal of a cure for each and every patient with a desmoid tumor. Typically, the Foundation is particularly interested in innovative and translational research projects and will consider applications across the spectrum of research from basic science to clinical trials and correlative studies.
Scroll down to review the application process.
Application Information
The Desmoid Tumor Research Foundation (DTRF) does not fund indirect costs associated with awarded grants. The DTRF will be accepting grant applications through the processes set out in the 2026 RFP details below.
Timeline and Requirements:
- LOI due: March 16, 2026 by 11:59PM ET
- LOI requirements: See page 5
- LOI notification: March 20, 2026
- If LOI is accepted, full application due: April 20, 2026 by 11:59PM ET
- Format for Full Targeted Applications: See page 5
- Award notification: August 21, 2026 (subject to change)
- Project start date: November 1, 2026 (estimated)
Background
The Desmoid Tumor Research Foundation (DTRF) is dedicated to facilitating and funding research that leads to a cure for desmoid tumors. Desmoid tumors (also known as aggressive fibromatosis, desmoid fibromatosis, and desmoid-type fibromatosis) are rare, locally invasive, soft tissue tumors that form in the connective tissues of the body. We fund research that uses cutting-edge science and creative clinical applications, in addition to novel approaches addressing potential leads based on prior research.
DTRF is particularly interested in innovative and translational research projects and will consider applications across the spectrum of research from basic science to clinical trials and correlative studies. The grant amount may be up to $65,000 USD per year for a grant term of one to three years. Investigators applying for pilot funding may apply for funding up to $30,000 USD per year for a grant term of one year. This is limited to those who may not have an established line of research in the desmoid tumor research space or who have an innovative pilot project idea to collect preliminary data in advance of future grant applications.
Purpose
The Desmoid Tumor Research Foundation (DTRF) invites investigator-initiated research proposals that advance the understanding, prevention, diagnosis, and treatment of desmoid tumors. This general call for proposals supports innovative basic, translational, clinical, and computational research across disciplines, with an emphasis on studies that have the potential to meaningfully impact patients. While proposals addressing any aspect of desmoid tumor biology or care are welcome, DTRF has a particular interest in research that deepens understanding of spontaneous regression or disease stabilization, as well as projects that explore novel or emerging therapeutic approaches. Cross-disciplinary collaborations and proposals with clear translational relevance are strongly encouraged.
See full RFP guidelines and application format here.
Forms for Reports (For Current Grantees)
DTRF Progress Report Requirements
Desmoid Cell Line at ATCC
Publicly available desmoid tumor immortal cell lines are now available for purchase at ATCC, a public biorepository based in Manassas, VA. These tumor-derived models can be used in basic research as well as pharmacological screening applications. Detailed information about these models can be found on the ATCC website and on the HCMI website. Discounted pricing is available to academic researchers.
Continue Exploring
Clinicians & Researchers Newsletter
Receive monthly updates about treatment advances, grant applications, clinical trials, CME opportunities, and more.
